Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs Merck & Co., Inc. — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $10.82, while Merck & Co., Inc. trades at $124.03 (market cap $305.12B). The key difference: Merck & Co., Inc. pays a 2.75% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | MRK | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $16.61 | $129.52 |
52-Week Low | $10.26 | $77.60 |
Market Cap | — | $305.12B |
Enterprise Value | — | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $10.78 with no significant daily movement, showing neutral technical signals overall. The ETF maintains a consistent weekly dividend distribution strategy, though recent analyst commentary highlights concerns about NAV erosion despite high yields. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance levels cluster tightly around $10-11.
The outlook remains cautious as the synthetic option strategy delivers high income but exposes investors to amplified downside risk. While weekly distributions provide income appeal, total returns have lagged the underlying Amazon stock, creating sustainability concerns for long-term investors seeking both income and capital appreciation.
MRK trades at $124.03, up 0.4% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 loss narrower than expected. Revenue grew to $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook remains positive with a consensus price target of $135.14, implying ~9% upside. Risks include rising debt levels and competitive pressures in pharma. Institutional ownership trends show increased buying, supporting bullish sentiment. Earnings growth and pipeline expansion are key catalysts, though macroeconomic and regulatory headwinds warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
